The BREVAGen breast cancer risk stratification test is a genetic test panel that examines a patient’s blood sample to detect the absence or presence of certain common genetic variations (SNPs).

The test is designed to help physicians assess breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient’s family and personal history.

The company said the BREVAGen test may be useful for women at intermediate risk of developing breast cancer, including those who have undergone breast biopsies, as the test will provide information that can help physicians recommend alternative courses of action, such as targeted surveillance or preventive therapy, on a personalized patient-by-patient basis.

Phenogen Science CEO Paul MacLeman said the US launch of BREVAGen follows the establishment of commercial capability in the US and the achievement of CLIA certification for the company’s accredited laboratory.